Bristol Myers Squibb develops and commercializes therapies for oncology, hematology, immunology, cardiovascular, and neurological diseases. Its portfolio includes immuno-oncology products, blood-cancer treatments, anticoagulation medicine, and cell therapies. The company invests in clinical pipelines and acquisitions to offset patent-related revenue pressure on mature medicines.
Bristol-Myers Squibb Co. (BMY) has a MarketKingdoms composite score of 66.3 (B), an B-range rating. It ranks 675th of 1,866 covered companies, 29th of 78 in Healthcare (sector average 64.4) and 4th of 13 in Drug Manufacturers - General. Scores as of 2026-10-26.
Its strongest lenses are Industry opportunity at 81 (Healthcare average 81) and Price (valuation) at 77 (Healthcare average 50). Its weakest lenses are Expansion (growth) at 23 (sector average 50) and Trend (momentum) at 52 (sector average 50).
| Lens | Type | BMY | Healthcare average | Drug Manufacturers - General average | Percentile in sector |
|---|---|---|---|---|---|
| Industry opportunity | Research signal | 81 | 81 | 81 | 65th |
| Stock selection | Research signal | 74 | 79 | 78 | 23rd |
| KPI momentum | Research signal | 71 | 78 | 77 | 29th |
| Catalyst watch | Research signal | 73 | 74 | 71 | 41st |
| Price (valuation) | Fundamental lens | 77 | 50 | 53 | 90th |
| Expansion (growth) | Fundamental lens | 23 | 50 | 39 | 10th |
| Quality (profitability) | Fundamental lens | 68 | 50 | 60 | 77th |
| Trend (momentum) | Fundamental lens | 52 | 50 | 55 | 51st |
The most recent call analysed was held on 2026-07-30 (fiscal 2026 Q2). After it the composite moved from 77.8 to 77.1. MarketKingdoms checks what management promised on each call against what it later delivered.
The composite at the time of each event; today's composite is 66.3.
The stock's valuation gap is -11.0%: its price is below the path its market, sector and industry moves explain (undervalued versus the model path). Factor sensitivity: market beta 1.02, sector beta -0.17, industry beta 1.03; the factor model explains 48% of its moves (R²).
| Company | Composite | Grade | Valuation gap |
|---|---|---|---|
| Amgen Inc. (AMGN) | 71.9 | B+ | +13.9% |
| Eli Lilly & Co. (LLY) | 71.2 | B+ | +1.7% |
| AbbVie Inc. (ABBV) | 69.0 | B | -3.2% |
| Biogen Inc. (BIIB) | 65.9 | B | +31.0% |
| Gilead Sciences Inc. (GILD) | 65.5 | B | -3.5% |
| GSK plc ADR (GSK) | 63.0 | B- | -5.1% |
| Novo Nordisk ADR (NVO) | 62.9 | B- | -24.0% |
| Novartis AG ADR (NVS) | 62.1 | B- | -3.9% |
Bristol-Myers Squibb Co. financial statements · Healthcare sector ranking · Drug Manufacturers - General industry ranking · All covered companies
The composite score (0–100, graded A+ to D-) blends research signals from each earnings call with fundamental lenses from SEC filings and market prices. Research signals: Industry opportunity, Stock selection, KPI momentum and Catalyst watch, read from what management said and whether it delivered. Fundamental lenses: Price (valuation), Expansion (growth), Quality (profitability) and Trend (momentum). Scores are recalculated every night and after every earnings call. The valuation gap compares the actual price path with the path the stock's market, sector and industry moves explain; it is a model comparison, not a fair-value estimate.
General information, not investment advice.